{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T23:04:54Z","timestamp":1788044694245,"version":"build-2784847793"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2011,6,10]],"date-time":"2011-06-10T00:00:00Z","timestamp":1307664000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1007\/s00262-011-1052-0","type":"journal-article","created":{"date-parts":[[2011,6,9]],"date-time":"2011-06-09T15:21:31Z","timestamp":1307632891000},"page":"1485-1495","source":"Crossref","is-referenced-by-count":22,"title":["Serum levels of cytoplasmic melanoma-associated antigen at diagnosis may predict clinical relapse in neuroblastoma patients"],"prefix":"10.1007","volume":"60","author":[{"given":"Fabio","family":"Morandi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Valeria","family":"Corrias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Levreri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Scaruffi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizzia","family":"Raffaghello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Carlini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Bocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignazia","family":"Prigione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Stigliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loredana","family":"Amoroso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soldano","family":"Ferrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Pistoia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,6,10]]},"reference":[{"issue":"5","key":"1052_CR1","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1080\/078538902320772070","volume":"34","author":"P Labdenne","year":"2002","unstructured":"Labdenne P, Heikinheimo M (2002) Clinical use of tumor markers in childhood malignancies. Ann Med 34(5):316\u2013323","journal-title":"Ann Med"},{"issue":"5","key":"1052_CR2","first-page":"877","volume":"6","author":"P Giacomini","year":"1986","unstructured":"Giacomini P, Gambari R, Barbieri R, Nistico P, Tecce R, Pestka S, Gustafsson K, Natali PG, Fisher PB (1986) Regulation of the antigenic phenotype of human melanoma cells by recombinant interferons. Anticancer Res 6(5):877\u2013884","journal-title":"Anticancer Res"},{"issue":"3","key":"1052_CR3","first-page":"1281","volume":"44","author":"P Giacomini","year":"1984","unstructured":"Giacomini P, Veglia F, Cordiali Fei P, Rehle T, Natali PG, Ferrone S (1984) Level of a membrane-bound high-molecular-weight melanoma-associated antigen and a cytoplasmic melanoma-associated antigen in surgically removed tissues and in sera from patients with melanoma. Cancer Res 44(3):1281\u20131287","journal-title":"Cancer Res"},{"issue":"19","key":"1052_CR4","first-page":"5175","volume":"47","author":"P Giacomini","year":"1987","unstructured":"Giacomini P, Viora M, Tecce R, Knowles DM, Natali PG, Ferrone S (1987) A cytoplasmic human melanoma associated antigen as a marker of activation in lymphoid cells. Cancer Res 47(19):5175\u20135180","journal-title":"Cancer Res"},{"issue":"11","key":"1052_CR5","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1158\/1078-0432.CCR-07-1842","volume":"14","author":"Y Goto","year":"2008","unstructured":"Goto Y, Ferrone S, Arigami T, Kitago M, Tanemura A, Sunami E, Nguyen SL, Turner RR, Morton DL, Hoon DS (2008) Human high molecular weight-melanoma-associated antigen: utility for detection of metastatic melanoma in sentinel lymph nodes. Clin Cancer Res 14(11):3401\u20133407","journal-title":"Clin Cancer Res"},{"issue":"11","key":"1052_CR6","doi-asserted-by":"crossref","first-page":"7104","DOI":"10.4049\/jimmunol.174.11.7104","volume":"174","author":"W Luo","year":"2005","unstructured":"Luo W, Hsu JC, Tsao CY, Ko E, Wang X, Ferrone S (2005) Differential immunogenicity of two peptides isolated by high molecular weight-melanoma-associated antigen-specific monoclonal antibodies with different affinities. J Immunol 174(11):7104\u20137110","journal-title":"J Immunol"},{"issue":"10","key":"1052_CR7","doi-asserted-by":"crossref","first-page":"6046","DOI":"10.4049\/jimmunol.176.10.6046","volume":"176","author":"W Luo","year":"2006","unstructured":"Luo W, Ko E, Hsu JC, Wang X, Ferrone S (2006) Targeting melanoma cells with human high molecular weight-melanoma associated antigen-specific antibodies elicited by a peptide mimotope: functional effects. J Immunol 176(10):6046\u20136054","journal-title":"J Immunol"},{"issue":"1","key":"1052_CR8","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/ijc.21820","volume":"119","author":"SR Reynolds","year":"2006","unstructured":"Reynolds SR, Vergilis IJ, Szarek M, Ferrone S, Bystryn JC (2006) Cytoplasmic melanoma-associated antigen (CYT-MAA) serum level in patients with melanoma: a potential marker of response to immunotherapy? Int J Cancer 119(1):157\u2013161","journal-title":"Int J Cancer"},{"issue":"3","key":"1052_CR9","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/j.0022-202X.2005.23798.x","volume":"125","author":"IJ Vergilis","year":"2005","unstructured":"Vergilis IJ, Szarek M, Ferrone S, Reynolds SR (2005) Presence and prognostic significance of melanoma-associated antigens CYT-MAA and HMW-MAA in serum of patients with melanoma. J Invest Dermatol 125(3):526\u2013531","journal-title":"J Invest Dermatol"},{"issue":"4","key":"1052_CR10","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/sj.jid.5700158","volume":"126","author":"A Ulmer","year":"2006","unstructured":"Ulmer A, Fierlbeck G (2006) Circulating tumor cells and detection of the melanoma-associated antigen HMW-MAA in the serum of melanoma patients. J Invest Dermatol 126(4):914\u2013915 author reply 915-916","journal-title":"J Invest Dermatol"},{"issue":"24","key":"1052_CR11","doi-asserted-by":"crossref","first-page":"8178","DOI":"10.1158\/1078-0432.CCR-08-0371","volume":"14","author":"S Wagner","year":"2008","unstructured":"Wagner S, Krepler C, Allwardt D, Latzka J, Strommer S, Scheiner O, Pehamberger H, Wiedermann U, Hafner C, Breiteneder H (2008) Reduction of human melanoma tumor growth in severe combined immunodeficient mice by passive transfer of antibodies induced by a high molecular weight melanoma-associated antigen mimotope vaccine. Clin Cancer Res 14(24):8178\u20138183","journal-title":"Clin Cancer Res"},{"issue":"19","key":"1052_CR12","doi-asserted-by":"crossref","first-page":"8066","DOI":"10.1158\/0008-5472.CAN-08-0287","volume":"68","author":"PC Maciag","year":"2008","unstructured":"Maciag PC, Seavey MM, Pan ZK, Ferrone S, Paterson Y (2008) Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature. Cancer Res 68(19):8066\u20138075","journal-title":"Cancer Res"},{"issue":"2","key":"1052_CR13","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1006\/bbrc.1997.6258","volume":"232","author":"N Tinari","year":"1997","unstructured":"Tinari N, D\u2019Egidio M, Iacobelli S, Bowen M, Starling G, Seachord C, Darveau R, Aruffo A (1997) Identification of the tumor antigen 90\u00a0K domains recognized by monoclonal antibodies SP2 and L3 and preparation and characterization of novel anti-90\u00a0K monoclonal antibodies. Biochem Biophys Res Commun 232(2):367\u2013372","journal-title":"Biochem Biophys Res Commun"},{"issue":"7\u20139","key":"1052_CR14","first-page":"551","volume":"19","author":"A Grassadonia","year":"2004","unstructured":"Grassadonia A, Tinari N, Iurisci I, Piccolo E, Cumashi A, Innominato P, D\u2019Egidio M, Natoli C, Piantelli M, Iacobelli S (2004) 90\u00a0K (Mac-2 BP) and galectins in tumor progression and metastasis. Glycoconj J 19(7\u20139):551\u2013556","journal-title":"Glycoconj J"},{"issue":"27","key":"1052_CR15","doi-asserted-by":"crossref","first-page":"18573","DOI":"10.1074\/jbc.M803115200","volume":"283","author":"Y Fukaya","year":"2008","unstructured":"Fukaya Y, Shimada H, Wang LC, Zandi E, DeClerck YA (2008) Identification of galectin-3-binding protein as a factor secreted by tumor cells that stimulates interleukin-6 expression in the bone marrow stroma. J Biol Chem 283(27):18573\u201318581","journal-title":"J Biol Chem"},{"issue":"4","key":"1052_CR16","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1600-0560.1983.tb01489.x","volume":"10","author":"PG Natali","year":"1983","unstructured":"Natali PG, Giacomini P, Russo C, Steinbach G, Fenoglio C, Ferrone S (1983) Antigenic profile of human melanoma cells. Analysis with monoclonal antibodies to histocompatibility antigens and to melanoma-associated antigens. J Cutan Pathol 10(4):225\u2013237","journal-title":"J Cutan Pathol"},{"issue":"6","key":"1052_CR17","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1002\/1097-0142(19900315)65:6<1325::AID-CNCR2820650613>3.0.CO;2-J","volume":"65","author":"G Scambia","year":"1990","unstructured":"Scambia G, Panici PB, Iacobelli S, Baiocchi G, Battaglia F, Perrone L, Sonsini C, Ferrandina G, Natoli C, Mancuso S (1990) Recombinant alpha-2b-interferon enhances the circulating levels of a 90-kilodalton (K) tumor-associated antigen in patients with gynecologic and breast malignancies. Cancer 65(6):1325\u20131328","journal-title":"Cancer"},{"issue":"7130","key":"1052_CR18","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/nature05661","volume":"445","author":"V Gray-Schopfer","year":"2007","unstructured":"Gray-Schopfer V, Wellbrock C, Marais R (2007) Melanoma biology and new targeted therapy. Nature 445(7130):851\u2013857","journal-title":"Nature"},{"issue":"6","key":"1052_CR19","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/jnr.10160","volume":"67","author":"PA Barker","year":"2002","unstructured":"Barker PA, Salehi A (2002) The MAGE proteins: emerging roles in cell cycle progression, apoptosis, and neurogenetic disease. J Neurosci Res 67(6):705\u2013712","journal-title":"J Neurosci Res"},{"issue":"3","key":"1052_CR20","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/(SICI)1097-4652(200003)182:3<323::AID-JCP2>3.0.CO;2-#","volume":"182","author":"C Castelli","year":"2000","unstructured":"Castelli C, Rivoltini L, Andreola G, Carrabba M, Renkvist N, Parmiani G (2000) T-cell recognition of melanoma-associated antigens. J Cell Physiol 182(3):323\u2013331","journal-title":"J Cell Physiol"},{"issue":"22","key":"1052_CR21","doi-asserted-by":"crossref","first-page":"10639","DOI":"10.1158\/0008-5472.CAN-06-2522","volume":"66","author":"MT Epping","year":"2006","unstructured":"Epping MT, Bernards R (2006) A causal role for the human tumor antigen preferentially expressed antigen of melanoma in cancer. Cancer Res 66(22):10639\u201310642","journal-title":"Cancer Res"},{"issue":"6","key":"1052_CR22","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/ijc.1282","volume":"92","author":"AA Jungbluth","year":"2001","unstructured":"Jungbluth AA, Chen YT, Stockert E, Busam KJ, Kolb D, Iversen K, Coplan K, Williamson B, Altorki N, Old LJ (2001) Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer 92(6):856\u2013860","journal-title":"Int J Cancer"},{"issue":"3","key":"1052_CR23","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrc1014","volume":"3","author":"GM Brodeur","year":"2003","unstructured":"Brodeur GM (2003) Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3(3):203\u2013216","journal-title":"Nat Rev Cancer"},{"issue":"9579","key":"1052_CR24","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(07)60983-0","volume":"369","author":"JM Maris","year":"2007","unstructured":"Maris JM, Hogarty MD, Bagatell R, Cohn SL (2007) Neuroblastoma. Lancet 369(9579):2106\u20132120","journal-title":"Lancet"},{"issue":"1","key":"1052_CR25","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.pcl.2007.10.014","volume":"55","author":"JR Park","year":"2008","unstructured":"Park JR, Eggert A, Caron H (2008) Neuroblastoma: biology, prognosis, and treatment. Pediatr Clin North Am 55(1):97\u2013120","journal-title":"Pediatr Clin North Am"},{"issue":"8","key":"1052_CR26","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1200\/JCO.1993.11.8.1466","volume":"11","author":"GM Brodeur","year":"1993","unstructured":"Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, De Bernardi B, Evans AE, Favrot M, Hedborg F et al (1993) Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11(8):1466\u20131477","journal-title":"J Clin Oncol"},{"issue":"3","key":"1052_CR27","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1055\/s-2008-1065345","volume":"220","author":"M Fischer","year":"2008","unstructured":"Fischer M, Spitz R, Oberthur A, Westermann F, Berthold F (2008) Risk estimation of neuroblastoma patients using molecular markers. Klin Padiatr 220(3):137\u2013146","journal-title":"Klin Padiatr"},{"issue":"1\u20132","key":"1052_CR28","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0304-3835(03)00094-6","volume":"197","author":"J Mora","year":"2003","unstructured":"Mora J, Gerald WL, Cheung NK (2003) Evolving significance of prognostic markers associated with new treatment strategies in neuroblastoma. Cancer Lett 197(1\u20132):119\u2013124","journal-title":"Cancer Lett"},{"issue":"13","key":"1052_CR29","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1016\/S0959-8049(03)00376-9","volume":"39","author":"T Simon","year":"2003","unstructured":"Simon T, Hero B, Hunneman DH, Berthold F (2003) Tumour markers are poor predictors for relapse or progression in neuroblastoma. Eur J Cancer 39(13):1899\u20131903","journal-title":"Eur J Cancer"},{"issue":"33","key":"1052_CR30","doi-asserted-by":"crossref","first-page":"8483","DOI":"10.1200\/JCO.2005.02.4661","volume":"23","author":"G Cecchetto","year":"2005","unstructured":"Cecchetto G, Mosseri V, De Bernardi B, Helardot P, Monclair T, Costa E, Horcher E, Neuenschwander S, Toma P, Rizzo A, Michon J, Holmes K (2005) Surgical risk factors in primary surgery for localized neuroblastoma: the LNESG1 study of the European International Society of Pediatric Oncology Neuroblastoma Group. J Clin Oncol 23(33):8483\u20138489. doi: 10.1200\/JCO.2005.02.4661","journal-title":"J Clin Oncol"},{"issue":"4","key":"1052_CR31","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1200\/JCO.2010.29.5196","volume":"29","author":"H Rubie","year":"2011","unstructured":"Rubie H, De Bernardi B, Gerrard M, Canete A, Ladenstein R, Couturier J, Ambros P, Munzer C, Pearson AD, Garaventa A, Brock P, Castel V, Valteau-Couanet D, Holmes K, Di Cataldo A, Brichard B, Mosseri V, Marquez C, Plantaz D, Boni L, Michon J (2011) Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1. J Clin Oncol 29(4):449\u2013455. doi: 10.1200\/JCO.2010.29.5196","journal-title":"J Clin Oncol"},{"issue":"3","key":"1052_CR32","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/08880010390158838","volume":"20","author":"N Olgun","year":"2003","unstructured":"Olgun N, Kansoy S, Aksoylar S, Cetingul N, Vergin C, Oniz H, Sarialioglu F, Kantar M, Uysal K, Tuncyurek M, Kargi A, Aktas S, Bayol U, Karaca I, Arikan A, Balik E, Aktug T, Elmas N, Kovanlikaya A, Kinay M, Anacak Y, Degirmenci B, Burak Z (2003) Experience of the izmir pediatric oncology group on neuroblastoma: IPOG-NBL-92 protocol. Pediatr Hematol Oncol 20(3):211\u2013218","journal-title":"Pediatr Hematol Oncol"},{"issue":"15","key":"1052_CR33","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1093\/jnci\/djh221","volume":"96","author":"C Brignole","year":"2004","unstructured":"Brignole C, Pastorino F, Marimpietri D, Pagnan G, Pistorio A, Allen TM, Pistoia V, Ponzoni M (2004) Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs. J Natl Cancer Inst 96(15):1171\u20131180","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"1052_CR34","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jconrel.2007.11.010","volume":"126","author":"F Pastorino","year":"2008","unstructured":"Pastorino F, Mumbengegwi DR, Ribatti D, Ponzoni M, Allen TM (2008) Increase of therapeutic effects by treating melanoma with targeted combinations of c-myc antisense and doxorubicin. J Control Release 126(1):85\u201394","journal-title":"J Control Release"},{"issue":"10","key":"1052_CR35","first-page":"2048","volume":"31","author":"S Chiesa","year":"2004","unstructured":"Chiesa S, Prigione I, Morandi F, Buoncompagni A, Picco P, Bocca P, Martini A, Pistoia V, Gattorno M (2004) Cytokine flexibility of early and differentiated memory T helper cells in juvenile idiopathic arthritis. J Rheumatol 31(10):2048\u20132054","journal-title":"J Rheumatol"},{"issue":"4","key":"1052_CR36","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25(4):402\u2013408","journal-title":"Methods"},{"issue":"4","key":"1052_CR37","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/clinchem\/39.4.561","volume":"39","author":"MH Zweig","year":"1993","unstructured":"Zweig MH, Campbell G (1993) Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 39(4):561\u2013577","journal-title":"Clin Chem"},{"issue":"1\u20132","key":"1052_CR38","first-page":"77","volume":"32","author":"MV Corrias","year":"2010","unstructured":"Corrias MV, Gambini C, Gregorio A, Croce M, Barisione G, Cossu C, Rossello A, Ferrini S, Fabbi M (2010) Different subcellular localization of ALCAM molecules in neuroblastoma: Association with relapse. Cell Oncol 32(1\u20132):77\u201386. doi: 10.3233\/CLO-2009-0494","journal-title":"Cell Oncol"},{"issue":"1","key":"1052_CR39","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.bone.2010.06.028","volume":"48","author":"D Granchi","year":"2011","unstructured":"Granchi D, Corrias MV, Garaventa A, Baglio SR, Cangemi G, Carlini B, Paolucci P, Giunti A, Baldini N (2011) Neuroblastoma and bone metastases: clinical significance and prognostic value of Dickkopf 1 plasma levels. Bone 48(1):152\u2013159. doi: 10.1016\/j.bone.2010.06.028","journal-title":"Bone"},{"issue":"1","key":"1052_CR40","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1365-2559.2008.03070.x","volume":"53","author":"A Gregorio","year":"2008","unstructured":"Gregorio A, Corrias MV, Castriconi R, Dondero A, Mosconi M, Gambini C, Moretta A, Moretta L, Bottino C (2008) Small round blue cell tumours: diagnostic and prognostic usefulness of the expression of B7\u2013H3 surface molecule. Histopathology 53(1):73\u201380. doi: 10.1111\/j.1365-2559.2008.03070.x","journal-title":"Histopathology"},{"issue":"9","key":"1052_CR41","first-page":"2535","volume":"62","author":"A Marchetti","year":"2002","unstructured":"Marchetti A, Tinari N, Buttitta F, Chella A, Angeletti CA, Sacco R, Mucilli F, Ullrich A, Iacobelli S (2002) Expression of 90\u00a0K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients. Cancer Res 62(9):2535\u20132539","journal-title":"Cancer Res"},{"issue":"4","key":"1052_CR42","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1046\/j.1365-2990.1999.00192.x","volume":"25","author":"L Gordower","year":"1999","unstructured":"Gordower L, Decaestecker C, Kacem Y, Lemmers A, Gusman J, Burchert M, Danguy A, Gabius H, Salmon I, Kiss R, Camby I (1999) Galectin-3 and galectin-3-binding site expression in human adult astrocytic tumours and related angiogenesis. Neuropathol Appl Neurobiol 25(4):319\u2013330","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"5","key":"1052_CR43","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/jcb.20784","volume":"98","author":"TA Ulmer","year":"2006","unstructured":"Ulmer TA, Keeler V, Loh L, Chibbar R, Torlakovic E, Andre S, Gabius HJ, Laferte S (2006) Tumor-associated antigen 90\u00a0K\/Mac-2-binding protein: possible role in colon cancer. J Cell Biochem 98(5):1351\u20131366","journal-title":"J Cell Biochem"},{"issue":"11","key":"1052_CR44","first-page":"3322","volume":"50","author":"T Hajto","year":"1990","unstructured":"Hajto T, Hostanska K, Frei K, Rordorf C, Gabius HJ (1990) Increased secretion of tumor necrosis factors alpha, interleukin 1, and interleukin 6 by human mononuclear cells exposed to beta-galactoside-specific lectin from clinically applied mistletoe extract. Cancer Res 50(11):3322\u20133326","journal-title":"Cancer Res"},{"issue":"19","key":"1052_CR45","first-page":"4530","volume":"56","author":"H Inohara","year":"1996","unstructured":"Inohara H, Akahani S, Koths K, Raz A (1996) Interactions between galectin-3 and Mac-2-binding protein mediate cell\u2013cell adhesion. Cancer Res 56(19):4530\u20134534","journal-title":"Cancer Res"},{"issue":"9","key":"1052_CR46","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/ijc.23296","volume":"122","author":"P Pocza","year":"2008","unstructured":"Pocza P, Suli-Vargha H, Darvas Z, Falus A (2008) Locally generated VGVAPG and VAPG elastin-derived peptides amplify melanoma invasion via the galectin-3 receptor. Int J Cancer 122(9):1972\u20131980. doi: 10.1002\/ijc.23296","journal-title":"Int J Cancer"},{"issue":"1","key":"1052_CR47","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1158\/0008-5472.CAN-08-0613","volume":"69","author":"T Ara","year":"2009","unstructured":"Ara T, Song L, Shimada H, Keshelava N, Russell HV, Metelitsa LS, Groshen SG, Seeger RC, DeClerck YA (2009) Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells. Cancer Res 69(1):329\u2013337","journal-title":"Cancer Res"},{"issue":"4","key":"1052_CR48","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.bbrc.2004.03.155","volume":"317","author":"Y Ozaki","year":"2004","unstructured":"Ozaki Y, Kontani K, Teramoto K, Fujita T, Tezuka N, Sawai S, Watanabe H, Fujino S, Asai T, Ohkubo I (2004) Identification of antigenic epitopes recognized by Mac-2 binding protein-specific cytotoxic T lymphocytes for use in cancer immunotherapy. Biochem Biophys Res Commun 317(4):1089\u20131095. doi: 10.1016\/j.bbrc.2004.03.155","journal-title":"Biochem Biophys Res Commun"},{"issue":"9","key":"1052_CR49","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1002\/cncr.10899","volume":"95","author":"Y Ozaki","year":"2002","unstructured":"Ozaki Y, Kontani K, Hanaoka J, Chano T, Teramoto K, Tezuka N, Sawai S, Fujino S, Yoshiki T, Okabe H, Ohkubo I (2002) Expression and immunogenicity of a tumor-associated antigen, 90\u00a0K\/Mac-2 binding protein, in lung carcinoma. Cancer 95(9):1954\u20131962. doi: 10.1002\/cncr.10899","journal-title":"Cancer"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-011-1052-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-011-1052-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-011-1052-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,20]],"date-time":"2020-06-20T00:26:00Z","timestamp":1592612760000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-011-1052-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,10]]},"references-count":49,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["1052"],"URL":"https:\/\/doi.org\/10.1007\/s00262-011-1052-0","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6,10]]}}}